China's State Intellectual Property Office has issued the first patent for the COVID-19 vaccine.
The patent was awarded to the Chinese People's Liberation Army Academy of Military Health Sciences and CanSino Biologics, which developed a recombinant vaccine against COVID-19.
Tests on mice and guinea pigs have shown that the vaccine has good immunogenicity and can cause an intense cellular and humoral immune response in a short period of time, RIA Novosti reported. In addition, the vaccine is easily and quickly prepared, which will ensure its mass production in a short time.
According to reports, six vaccines have already been released for clinical trials in China. Chinese experts have been researching and developing different types of vaccines from COVID-19 since the beginning of the epidemic, but only recombinant and inactive vaccines are allowed to be tested in humans.